Cannabinoid Encyclopedia

How cannabinoids work

What is CYP enzymes?

A simple explanation of CYP enzymes, why cannabinoid researchers study it, and what its biology can and cannot tell us.

Updated July 2026 16 research sources Human and early research

The short answer

Where CYP enzymes fits into cannabinoid biology

CYP enzymes is a biological target studied to understand how cannabinoids affect cells and signaling. Research on THC, Endocannabinoids, and CBDV helps explain possible mechanisms. This page brings together 5 human-study sources, 8 research reviews, and 3 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. A mechanism alone does not prove that a cannabinoid will produce a health benefit in people. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CYP enzymes.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on CYP enzymes covers THC, Endocannabinoids, and CBDV; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about CYP enzymes

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human research included

THC

Studies examine how THC connects with CYP enzymes or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 2

Human and early-stage research

Endocannabinoids

Studies examine how Endocannabinoids connects with CYP enzymes or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Mostly preclinical

CBDV

Studies examine how CBDV connects with CYP enzymes or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 4

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

5 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

8 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

3 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CYP enzymes is not one kind of study. This source set includes 8 narrative or expert reviews, 5 animal studies, and 1 clinical study in people. 3

The recorded populations or models include people or patients (6 sources), animal models (3 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is endocannabinoid enzyme activity or metabolic mechanisms (16 sources). Closely related outcome names can still describe different measurements. 5

The CYP enzymes source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

narrative or expert review

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

On this page, this source examines THC activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

narrative or expert review

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 3

Study type
narrative or expert review
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

clinical study in people

Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.

On this page, this source examines CBDV activity involving endocannabinoid enzyme activity or metabolic mechanisms. 4

Study type
clinical study in people
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
preclinical research

human research

Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 5

Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on CYP enzymes should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What does CYP enzymes do?

CYP enzymes is studied as part of cannabinoid-related biology and signaling. The exact role depends on the tissue, compound, and experimental setting. 7

Does a biological mechanism prove a health effect?

No. A mechanism can explain why an idea is plausible, but human studies are needed to test whether it changes a health outcome. 8

What research is linked to CYP enzymes?

The main areas on this page include THC, Endocannabinoids, and CBDV. The source links show the study type behind each area. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited PubMed 34959715 DOI 10.3390/ph14121316
  2. 2
    FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited PubMed 20047159
  3. 3
    Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited PubMed 32203086 DOI 10.1038/s41401-020-0385-7
  4. 4
    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
  5. 5
    Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research PubMed 22969151 DOI 10.1194/jlr.m030411
  6. 6
    Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research PubMed 32829065 DOI 10.1016/j.bbalip.2020.158807
  7. 7
    Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited PubMed 39747798 DOI 10.1007/7854_2024_563
  8. 8
    Critical enzymes involved in endocannabinoid metabolism. narrative or expert review; evidence still limited PubMed 17346227 DOI 10.2174/092986607780090829
  9. 9
    Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. narrative or expert review; evidence still limited PubMed 30564946 DOI 10.1007/s00726-018-2682-8
  10. 10
    The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? narrative or expert review; evidence still limited PubMed 34217798 DOI 10.1016/j.brainresbull.2021.06.022
  11. 11
    The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
  12. 12
    Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. animal study; preclinical research PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
See all 16 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research / 1 linked research note PubMed 34179865
  2. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited / 1 linked research note PubMed 32203086
  3. Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. animal study; mechanism-focused research / 1 linked research note PubMed 40269679
  4. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? narrative or expert review; evidence still limited / 1 linked research note PubMed 34217798
  5. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited / 1 linked research note PubMed 20047159
  6. Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 34959715
  7. Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. animal study; mechanism-focused research / 1 linked research note PubMed 41092478
  8. Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. animal study; preclinical research / 1 linked research note PubMed 24346263
  9. Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression. animal study; mechanism-focused research / 1 linked research note PubMed 39245706
  10. Critical enzymes involved in endocannabinoid metabolism. narrative or expert review; evidence still limited / 1 linked research note PubMed 17346227
  11. Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited / 1 linked research note PubMed 39747798
  12. Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. narrative or expert review; evidence still limited / 1 linked research note PubMed 30564946
  13. Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research / 1 linked research note PubMed 32829065
  14. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 21418147
  15. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. animal study; preclinical research / 1 linked research note PubMed 30075103
  16. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research / 1 linked research note PubMed 22969151